Reproductive Genetics Market Scope
Reproductive Genetics is concerned with the genetic and epigenetic aspects of both natural and assisted reproduction. Because of the rapid technological advances, it is a field that is constantly evolving, and it is our focus to constantly explore how technologies can be used to help understand the biology of reproduction. Individuals who want to know and/or have some control over their children's genetic makeup are using genetic reproductive technologies for a variety of reasons. A variety of techniques enables doctors to obtain genetic material from a foetus in the womb and analyse it genetically. Simultaneously, the advancement of technologies for creating embryos in a lab - the process of in vitro fertilisation (IVF) - has resulted in the ability to perform genetic analysis on these embryos prior to implanting them into the womb. These reproductive technologies enable us to screen, select, and, one day; modify offspring to eliminate deadly or crippling diseases. Simultaneously, they raise concerns about disability rights, discrimination, and eugenics.
|Unit||Value (USD Million)|
|Key Companies Profiled||Agilent Technologies, Inc. (United States), BGI (China), CENTOGENE AG (Germany), Fulgent Genetics, Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Igenomix (Spain), Illumina, Inc. (United States), Invitae Corporation (United States), Laboratory Corporation of America Holdings (United States) and PerkinElmer, Inc. (United States)|
To entice more end users, market players are focusing on providing Reproductive Genetics of higher quality while adhering to all regulatory standards. In the global reproductive genetics market, there are numerous large and small-scale service providers. They are also concentrating on the implementation of numerous advanced technologies. Furthermore, the numerous industry profits have led to the entry of new players, raising the level of rivalry in an already competitive market. The reproductive genetics market is currently expanding due to the rapid advancement of molecular science and the increased use of genetic tests. Some of the market's key players' strategies include new product offerings, product approvals, partnerships and alliances, mergers and acquisitions, and business expansions. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Reproductive Genetics market throughout the predicted period.
Agilent Technologies, Inc. (United States), BGI (China), CENTOGENE AG (Germany), Fulgent Genetics, Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Igenomix (Spain), Illumina, Inc. (United States), Invitae Corporation (United States), Laboratory Corporation of America Holdings (United States) and PerkinElmer, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Myriad Genetics, Inc. (United States), OPKO Health, Inc. (United States), Quest Diagnostics (United States), QIAGEN N.V. (Germany) and Thermo Fisher Scientific Inc. (United States).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
The study have segmented the market of Global Reproductive Genetics market by Type , by Application (Aneuploidy, Single Gene Disorders, Structural Abnormalities and Others) and Region with country level break-up.
On the basis of geography, the market of Reproductive Genetics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2021.
Market Leaders and their expansionary development strategiesIn February 2022, Agilent Technologies Inc. announced it has acquired advanced artificial intelligence (AI) technology developed by Virtual Control, an AI and machine teaching software developer that creates innovative analysis solutions in lab testing. Agilent will integrate the software, known as ACIES, into its industry-leading gas chromatography and mass spectrometry (GS/MS) platforms to improve the productivity, efficiency, and accuracy of high-throughput labs the company serves around the world.
OneCellDx and the Genetics Institute of America said on May 2022 that they have signed a diagnostics commercialization agreement for OneCellDx's OncoPredikt HRD Assay. Under the deal, GIA will create a laboratory-developed test based on OneCellDx's proprietary, artificial intelligence-enabled algorithm and assay, which is designed to identify genomic signatures associated with homologous recombination deficiency in cancer patients.
Analysis of current law demonstrates that the responses of state and federal governments and the legal system to reproductive genetic testing both have shaped the development of and reflect society's views about these techniques. Access to testing has been increased by the governmental provision of services and enactment of insurance requirements and by the state courts' frequent approval of individual litigants' claims that they were inappropriately denied genetic information. Many state legislatures, however, have tried to limit testing by failing to provide funds, forbidding private lawsuits, and by limiting access to abortion.
Reproductive Genetics Market Dynamics:
|Trends Influencing Market|
- Declining Cost of Genetic Sequencing Technologies and Rising Emphasis on Early Detection and Prevention has Been Contributing towards Market Growth.
- Ethical and Social Issues Related to Selection of gender and Others Have Been Restraining the Market Growth.
- Lack of Regulations had made it Convenient to Perform the Process with Approval and Have Non-Medical Use, Which Has Been Challenging for the Market.
- Shifting of Reimbursement Policies toward Enhanced Genetic Testing Coverage and Rising Funding and Innovations have Been Increasing Consumer Demand, Which Will Be Providing Better Opportunities for Market Growth.
Key Target AudienceBiotechnology companies, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others